サマリー

AAV受託開発・製造機関市場の成長・トレンド

Grand View Research, Inc.の新しいレポートによると、世界のAAV受託開発・製造機関の市場規模は2035年までに47億米ドルに達すると予想され、2023年から2035年までの年平均成長率は17.1％で拡大すると予測されています。この市場の主な促進要因は、遺伝子治療＆ワクチン用のアデノ随伴ウイルス（AAV）の強固なパイプライン、アデノ随伴ウイルスベクターの製造における技術的進歩、主要市場プレーヤーが様々な戦略をとっている競争の激しい市場である。例えば、2022年9月、Rocket Pharmaceuticals, Inc.は、精密医薬品の提供に注力するバイオテクノロジー企業、Renovacor, Inc.を買収しました。この買収は、アデノ随伴ウイルス（AAV）を用いた心疾患の遺伝子治療のパイオニアとしての地位を強化する同社の狙いに沿ったものです。

致死的な疾患や重篤な障害を持つ疾患に対応するAAVを介した遺伝子治療製品は、近年、学術的な新興企業への投資や、大手製薬会社による臨床試験を開始したいくつかの製品によって、急増している。AAVベクターは、がんだけでなく、循環器系、神経系、免疫系の病気にも有効な治療法として注目されています。これらの要因から、市場参加者やCDMOは、M&A、事業拡大、製品発売、共同研究、パートナーシップなどの戦略を実行しています。

遺伝子治療や遺伝子改変細胞治療の分野では、過去10年間にウイルスベクターの使用において大きな進歩がありました。ベンダーは、ウイルスベクター製造の特殊なニーズをサポートするために、業界の継続的な改善努力の一環として、既存の技術を革新してきました。このような開発には、接着性細胞培養のためのiCELLis技術の導入や、ウイルスベクター製造のためのクロマトグラフィー樹脂の作成が含まれます。さらに、液滴デジタルポリメラーゼ連鎖反応（ddPCR）、分析的超遠心分離（AUC）、サイズ排除クロマトグラフィー-多角度光散乱（SEC-MALS）、キャピラリー電気泳動-ドデシル硫酸ナトリウム（CE-SDS）などの次世代分析は、正確で精密な定量を容易にします。

AAV受託開発・製造機関市場レポートハイライト

- 2022年の売上シェアは54.8%で、下流処理部門が市場を支配しています。この市場の主なドライバーは、AAVカプシドのサイズが小さく、他のウイルスと比較して非常に安定しているため、AAVベクターの精製が比較的容易であることです

- 培養タイプに基づくと、2022年には付着性培養セグメントが58.9％の最大の収益シェアを占めています。3次元プラットフォームに比べ、生物工学の専門的な知識を必要としないため

- エンドユーザー別では、製薬会社およびバイオ医薬品会社が2022年に53.5%の収益シェアを獲得して市場を支配し、予測期間中も最も高い成長を示すと予測されている

- アジア太平洋地域は、予測期間中に19.7%という最も速いCAGRを記録すると予測されています。患者数の多さ、全体的なコストの低さ、熟練した労働力、規制シナリオの変化が市場成長を促進する主な要因です。

ページTOPに戻る

目次

Table of Contents

Chapter 1 Report Scope
1.1 Segment Market Scope
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
Chapter 2 Research Methodology
2.1 Research Methodology
2.1.1 Information Procurement
2.2 Information Or Data Analysis
2.3 Market Formulation & Validation
2.4 Region-Wise Market Calculation
2.4.1 Approaches Used To Estimate The Market Size
2.4.1.1 Approach 1: Region-Wise Market Estimation Using Bottom-Up Approach
2.4.1.2 Approach 2: Parent Market Analysis
2.4.1.3 Approach 3: Commodity Flow (Company Share Analysis)
2.4.2 Global Market: CAGR Calculation
2.4.3 Global AAV Cdmo Market Calculation, Methodology, And Assumptions
2.5 Model Details
2.5.1 Commodity Flow Analysis
2.6 List Of Secondary Sources
2.7 Primary Research:
2.7.1 Primary Sources
2.7.1.1 Data For Primary Interviews In North America
2.7.1.2 Data For Primary Interviews In Europe
2.7.1.3 Data For Primary Interviews In Asia Pacific
2.7.1.4 Data For Primary Interviews In Latin America
2.7.1.5 Data For Primary Interviews In Mea
2.8 List Of Abbreviations
2.9 Objectives
2.9.1 Objective - 1:
2.9.2 Objective - 2:
2.9.3 Objective - 3:
2.9.4 Objective - 4:
Chapter 3 Executive Summary
3.1 Market Snapshot
3.2 Segment Snapshot
3.3 Competitive Landscape Snapshot
Chapter 4 Pharmaceutical Dissolution Testing Services Market Variables, Trends, and Scope
4.1 Market Lineage Outlook
4.1.1 Parent Market Outlook
4.1.2 Ancillary Market Outlook
4.2 Market Driver Analysis
4.2.1. Robust pipeline of adeno-associated virus for gene therapies and vaccines
4.2.2 Technological advancements in manufacturing adeno - associated viral vectors
4.2.3 Highly competitive Market & various strategies undertaken by Market entities
4.2.3.1 Acquisitions
4.2.3.2 Collaboration
4.2.3.3 Expansion
4.2.3.4 Partnership
4.3 Market Restraint Analysis
4.3.1 Regulatory, scientific, and ethical challenges associated with gene therapy & viral vectors
4.3.2 Manufacturing challenges in producing AAV viral vectors
4.4 AAV Cdmo Market: Analysis Tools
4.4.1 Porter’s Five Forces Analysis
4.4.2 PEST Analysis
4.5 Impact Of COVID-19 On AAV Cdmo Market
4.5.1 COVID - 19 Impact
4.5.2 COVID - 19 Reformation Strategies
Chapter 5 Global Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market
5.1 Definitions & Scope
5.2 Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations: Market Share Analysis, 2022 & 2035
5.3 Upstream Processing
5.3.1 Upstream Processing Market, 2018 - 2035 (USD Million)
5.3.2 Vector Amplification & Expansion
5.3.2.1 Vector Amplification & Expansion Market, 2018 - 2035 (USD Million)
5.3.3 Vector Recovery & Harvesting
5.3.3.1 Vector Recovery & Harvesting Market, 2018 - 2035 (USD Million)
5.4 Downstream Processing
5.4.1 Downstream Processing Market, 2018 - 2035 (USD Million)
5.4.2 Purification
5.4.2.1 Purification Market, 2018 - 2035 (USD Million)
5.4.3 Fill Finish
5.4.3.1 Fill Finish Market, 2018 - 2035 (USD Million)
Chapter 6 Global Adeno - Associated Virus Contract Development & Manufacturing Market: Culture Type Segment Analysis
6.1 Definitions & Scope
6.2 Adeno - Associated Virus Contract Development & Manufacturing Organizations: Market Share Analysis, 2022 & 2035
6.3 Adherent Culture
6.3.1 Adherent Culture Market, 2018 - 2035 (USD Million)
6.4 Suspension Culture
6.4.1 Suspension Culture Market, 2018 - 2035 (USD Million)
Chapter 7 Global Adeno - Associated Virus Contract Development & Manufacturing Organizations Market: Application Segment Analysis
7.1 Definitions & Scope
7.2 Adeno - Associated Virus Contract Development & Manufacturing Organizations: Market Share Analysis, 2022 & 2035
7.3 Cell & Gene Therapy Development
7.3.1 Cell & Gene Therapy Development Market, 2018 - 2035 (USD Million)
7.4 Vaccine Development
7.4.1 Vaccine Development Market, 2018 - 2035 (USD Million)
7.5 Biopharmaceutical and Pharmaceutical Discovery
7.5.1 Biopharmaceutical and Pharmaceutical Discovery Market, 2018 - 2035 (USD Million)
7.6 Biomedical Research
7.6.1 Biomedical Research Market, 2018 - 2035 (USD Million)
Chapter 8 Global Adeno - Associated Virus Contract Development & Manufacturing Organizations Market: End Use Segment Analysis
8.1 Definitions & Scope
8.2 Adeno - Associated Virus Contract Development & Manufacturing Organizations: Market Share Analysis, 2022 & 2035
8.3 Pharmaceutical and Biopharmaceutical Companies
8.3.1 Pharmaceutical and Biopharmaceutical Companies Market, 2018 - 2035 (USD Million)
8.4 Academic & Research Institutes
8.4.1 Academic Research Institutes Market, 2018 - 2035 (USD Million)
Chapter 9 Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market: Regional Estimates and Trend Analysis
9.1.1 North America
9.1.2 SWOT Analysis:
9.1.2.1 North America Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.3 U.S.
9.1.3.1 Key Country Dynamics
9.1.3.2 Target Disease Prevalence
9.1.3.1 Competetive Scenario
9.1.3.2 Regulatory Framework
9.1.3.3 U.S. Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.4 Canada
9.1.4.1 Key Country Dynamics
9.1.4.2 Competitive Scenario
9.1.4.3 Regulatory Framework
9.1.4.4 Canada Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.5 Europe
9.1.6 SWOT Analysis:
9.1.6.1 Europe Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.7 U.K.
9.1.7.1 Key Country Dynamics
9.1.7.2 Competitive Scenario
9.1.7.3 Regulatory Framework
9.1.7.4 U.K. Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.8 Germany
9.1.8.1 Key Country Dynamics
9.1.8.2 Competitive Scenario
9.1.8.3 Regulatory Framework
9.1.8.4 Germany Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.9 France
9.1.9.1 Key Country Dynamics
9.1.9.2 Competitive Scenario
9.1.9.3 Regulatory Framework
9.1.9.4 France Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.10 Italy
9.1.10.1 Key Country Dynamics
9.1.10.2 Competitive Scenario
9.1.10.3 Regulatory Framework
9.1.10.4 Italy Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.11 Spain
9.1.11.1 Key Country Dynamics
9.1.11.2 Competitive Scenario
9.1.11.3 Regulatory Framework
9.1.11.4 Spain Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.12 Denmark
9.1.12.1 Key country dynamics
9.1.12.2 Competitive scenario
9.1.12.3 Regulatory framework
9.1.12.4 Denmark Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.13 Norway
9.1.13.1 Key country dynamics
9.1.13.2 Competitive scenario
9.1.13.3 Regulatory framework
9.1.13.4 Norway generic Contract Manufacturing Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.14 Sweden
9.1.14.1 Key country dynamics
9.1.14.2 Competitive scenario
9.1.14.3 Regulatory framework
9.1.14.4 Sweden Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.15 Belgium
9.1.15.1 Key country dynamics
9.1.15.2 Competitive scenario
9.1.15.3 Regulatory framework
9.1.15.4 Belgium Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.16 Switzerland
9.1.16.1 Key country dynamics
9.1.16.2 Competitive scenario
9.1.16.3 Regulatory framework
9.1.16.4 Switzerland Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.17 Netherland
9.1.14.1 Key country dynamics
9.1.14.2 Competitive scenario
9.1.14.3 Regulatory framework
9.1.14.4 Netherland Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.18 FINLAND
9.1.18.1 Key country dynamics
9.1.18.2 Competitive scenario
9.1.18.3 Regulatory framework
9.1.18.4 FINLAND Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.19 Asia Pacific
9.1.20 SWOT Analysis:
9.1.21 Asia Pacific antibody drug conjugates contract manufacturing organization Market, 2019 - 2035 (USD Million)
9.1.22 Japan
9.1.22.1 Key country dynamics
9.1.22.2 Competitive scenario
9.1.22.3 Regulatory framework
9.1.22.4 Japan generic Contract Manufacturing Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.23 China
9.1.23.1 Key country dynamics
9.1.23.2 Competitive scenario
9.1.23.3 Regulatory framework
9.1.23.4 China generic Contract Manufacturing Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.24 India
9.1.24.1 Key country dynamics
9.1.24.2 Competitive scenario
9.1.24.3 Regulatory framework
9.1.24.4 India generic Contract Manufacturing Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.25 South Korea
9.1.25.1 Key country dynamics
9.1.25.2 Competitive scenario
9.1.25.3 Regulatory framework
9.1.25.4 South Korea vessel sealing devices Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.26 Australia
9.1.26.1 Key country dynamics
9.1.26.2 Competitive scenario
9.1.26.3 Regulatory framework
9.1.26.4 Australia generic Contract Manufacturing Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.27 Singapore
9.1.27.1 Key country dynamics
9.1.27.2 Competitive scenario
9.1.27.3 Regulatory framework
9.1.27.4 Singapore Adeno - Associated Virus (AAV) contract development and manufacturing organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.28 Latin America
9.1.29 SWOT Analysis:
9.1.30 Latin America Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market, 2019 - 2035 (USD Million)
9.1.31 Brazil
9.1.31.1 Key country dynamics
9.1.31.2 Competitive scenario
9.1.31.3 Regulatory framework
9.1.31.4 Brazil Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.32 Mexico
9.1.32.1 Key country dynamics
9.1.32.2 Competitive scenario
9.1.32.3 Regulatory framework
9.1.32.4 Mexico Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.33 Argentina
9.1.33.1 Key country dynamics
9.1.33.2 Competitive scenario
9.1.33.3 Regulatory framework
9.1.33.4 Argentina Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.34 MEA
9.1.35 SWOT Analysis:
9.1.36 MEA Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market, 2019 - 2035 (USD Million)
9.1.37 South Africa
9.1.37.1 Key country dynamics
9.1.37.2 Competitive scenario
9.1.37.3 Regulatory framework
9.1.37.4 South Africa Adeno - Associated Virus (AAV) Contract Development and Manufacturing Organizations Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.38 SAUDI ARABIA
9.1.38.1 Key country dynamics
9.1.38.2 Competitive scenario
9.1.38.3 Regulatory framework
9.1.38.4 Saudi Arabia Generic Drug Contract Manufacturing Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.39 UAE
9.1.39.1 Key country dynamics
9.1.39.2 Competitive scenario
9.1.39.3 Regulatory framework
9.1.39.4 UAE Generic Drug Contract Manufacturing Market estimates and forecasts, 2019 - 2035 (USD Million)
9.1.40 KUWAIT
9.1.40.1 Key country dynamics
9.1.40.2 Competitive scenario
9.1.40.3 Regulatory framework
9.1.40.4 Kuwait Adeno - Associated Virus Contract Manufacturing Market Estimates and forecasts, 2019 - 2035 (USD Million)
Chapter 10 Competitive Landscape
10.1 AAV Service Heatmap Analysis
10.2 Recent development & strategic initiative analysis
10.3 Company Profile
10.4 Thermo Fischer Scientific, Inc.
10.1.1 Company Overview
10.1.2 Service Benchmarking
10.1.3 Financial Performance
10.1.4 Strategic Initiatives
10.5 Creative Biogene
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Service Benchmarking
10.5.4 Strategic Initiatives
10.6 Catalent Inc.
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.2 Service Benchmarking
10.6.3 Strategic Initiatives
10.7 Charles River Laboratories International, Inc.
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Service Benchmarking
10.7.4 Strategic Initiatives
10.8 Danaher (Aldevron)
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Service Benchmarking
10.8.4 Strategic Initiatives
10.9 Genezen
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Service Benchmarking
10.9.4 Strategic Initiatives
10.10 ViroCell Biologics
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Service Benchmarking
10.10.4 Strategic Initiatives
10.11 Merck KGaA
10.11.1 Company Overview
10.11.2 Financial Performance
10.11.3 Service Benchmarking
10.11.4 Strategic Initiatives
10.12 VIRALGEN
10.12.1 Company Overview
10.12.2 Financial Performance
10.12.3 Service Benchmarking
10.12.4 Strategic Initiatives
10.13 Biovian Oy
10.13.1 Company Overview
10.13.2 Financial Performance
10.13.3 Service Benchmarking
10.13.4 Strategic Initiatives
10.14 Esco Lifesciences (Esco Aster Pte. Ltd. )
10.14.1 Company Overview
10.14.2 Financial Performance
10.14.3 Service Benchmarking
10.14.4 Strategic Initiatives
10.15 GenScript ProBio
10.15.1 Company Overview
10.15.2 Financial Performance
10.15.3 Service Benchmarking
10.15.4 Strategic Initiatives
10.16 Porton Advanced Solution Ltd
10.16.1 Company Overview
10.16.2 Financial Performance
10.16.3 Service Benchmarking
10.16.4 Strategic Initiatives
10.17 Ask Bio
10.17.1 Company Overview
10.17.2 Financial Performance
10.17.3 Service Benchmarking
10.17.4 Strategic Initiatives
10.18 Showa Denko
10.18.1 Company Overview
10.18.2 Financial Performance
10.18.3 Service Benchmarking
10.18.4 Strategic Initiatives
10.19 Takara Bio, Inc.
10.19.1 Company Overview
10.19.2 Financial Performance
10.19.3 Service Benchmarking
10.19.4 Strategic Initiatives
10.20 ABL Manufacturing
10.20.1 Company Overview
10.20.2 Financial Performance
10.20.3 Service Benchmarking
10.20.4 Strategic Initiatives
10.21 Oxford Biomedica
10.21.1 Company Overview
10.21.2 Financial Performance
10.21.3 Service Benchmarking
10.21.4 Strategic Initiatives
10.22 Belief Biomed, Inc.
10.22.1 Company Overview
10.22.2 Financial Performance
10.22.3 Service Benchmarking
10.22.4 Strategic Initiatives
10.23 Beijing Anlong Biomedicine Co., Ltd
10.23.1 Company Overview
10.23.2 Financial Performance
10.23.3 Service Benchmarking
10.23.4 Strategic Initiatives
10.24 Forecyte Bio Limited
10.24.1 Company Overview
10.24.2 Financial Performance
10.24.3 Service Benchmarking
10.24.4 Strategic Initiatives
10.25 Gene Pharma, Inc.
10.25.1 Company Overview
10.25.2 Financial Performance
10.25.3 Service Benchmarking
10.25.4 Strategic Initiatives
10.26 Skyline Therapeutics
10.26.1 Company Overview
10.26.2 Financial Performance
10.26.3 Service Benchmarking
10.26.4 Strategic Initiatives
10.27 TFBS Bioscience, Inc.
10.27.1 Company Overview
10.27.2 Financial Performance
10.27.3 Service Benchmarking
10.27.4 Strategic Initiatives